Morgan Stanley analyst Judah Frommer has maintained their bullish stance on BCAX stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Judah Frommer has given his Buy rating due to a combination of factors surrounding Bicara Therapeutics Inc. (BCAX). The company is actively competing in the Head & Neck Cancer (HNSCC) market, particularly focusing on the HPV-negative patient population. The ongoing FORTIFI-HN01 Phase 2/3 study is expanding its reach, with plans to significantly increase the number of trial sites, which could enhance its market presence and data collection capabilities.
Additionally, Frommer notes that both Bicara’s ficerafusp alfa and Merus’ petosemtamab have shown potential to improve the standard of care in HNSCC. Despite the limited patient numbers and follow-up, the response rates for ficerafusp alfa in combination with pembrolizumab are comparable to those of petosemtamab. Given the unmet need in this cancer type and the potential for market share in the HPV-negative segment, Frommer sees a promising opportunity for BCAX, warranting a Buy rating.
Frommer covers the Healthcare sector, focusing on stocks such as Galapagos, RegenXBio, and PTC Therapeutics. According to TipRanks, Frommer has an average return of -3.7% and a 49.33% success rate on recommended stocks.
In another report released yesterday, JonesTrading also maintained a Buy rating on the stock with a $22.00 price target.